Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$8.44 USD
-0.53 (-5.91%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.42 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NRIX 8.44 -0.53(-5.91%)
Will NRIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Other News for NRIX
Technical picture remains unchanged for NRIX after it falls 5.91% on September 20
NRIX forms Stochastic Buy Signal on September 18
Pocket Pivot appears for NRIX after 1.54% move
Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus
Nurix Therapeutics (NRIX) Gets a Buy from Barclays